indomethacin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anti-inflammatory, indometacin derivatives	1440	53-86-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: indomethacin hydrochloride indomethacin HCl indocin indomethacin indometacine indomethacine indometacin indomethacin sodium	A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Additional data needed to determine whether in vitro activity against SARS-CoV-2 corresponds with clinical efficacy in the treatment of COVID-19. Molecular weight: 357.79 Formula: C19H16ClNO4 CLOGP: 4.18 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 68.53 ALOGS: -5.17 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

indomethacin hydrochloride
indomethacin HCl
indocin
indomethacin
indometacine
indomethacine
indometacin
indomethacin sodium

A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Additional data needed to determine whether in vitro activity against SARS-CoV-2 corresponds with clinical efficacy in the treatment of COVID-19.

Molecular weight: 357.79
Formula: C19H16ClNO4
CLOGP: 4.18
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 68.53
ALOGS: -5.17
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O
0.10	g	P
0.10	g	R
0.10	g	O
0.10	g	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	15 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	7.99 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 10, 1965	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neck deformity	167.68	12.36	49	14975	1805	46669233
Neck mass	147.71	12.36	51	14973	3242	46667796
Bone density abnormal	120.11	12.36	43	14981	3041	46667997
Disability	100.75	12.36	54	14970	10113	46660925
Drug hypersensitivity	98.76	12.36	232	14792	243593	46427445
Ankylosing spondylitis	90.68	12.36	44	14980	6693	46664345
Oligohydramnios	89.92	12.36	41	14983	5424	46665614
Premature baby	69.90	12.36	53	14971	18059	46652979
Mood swings	68.18	12.36	50	14974	16202	46654836
Neonatal disorder	66.69	12.36	19	15005	638	46670400
Premature delivery	58.69	12.36	52	14972	22017	46649021
Limb deformity	47.05	12.36	23	15001	3553	46667485
Anti-cyclic citrullinated peptide antibody positive	46.75	12.36	43	14981	19102	46651936
Exposure during pregnancy	44.77	12.36	104	14920	108108	46562930
Death	43.78	12.36	27	14997	335521	46335517
Joint stiffness	40.93	12.36	47	14977	27061	46643977
Corneal perforation	39.77	12.36	12	15012	494	46670544
Rheumatoid factor positive	38.79	12.36	40	14984	20421	46650617
Maternal drugs affecting foetus	37.70	12.36	23	15001	5495	46665543
Low birth weight baby	32.96	12.36	21	15003	5413	46665625
Hypermobility syndrome	32.33	12.36	11	15013	668	46670370
Drug ineffective	31.37	12.36	344	14680	677494	45993544
Hypercholesterolaemia	30.32	12.36	27	14997	11503	46659535
Oesophageal spasm	29.84	12.36	14	15010	1975	46669063
Neonatal respiratory distress syndrome	29.51	12.36	15	15009	2518	46668520
Joint swelling	29.05	12.36	118	14906	165955	46505083
Serotonin syndrome	28.45	12.36	37	14987	24183	46646855
Musculoskeletal stiffness	27.03	12.36	81	14943	97912	46573126
Oesophageal pain	26.58	12.36	14	15010	2529	46668509
Arthralgia	26.42	12.36	204	14820	364399	46306639
Therapeutic product effect decreased	26.39	12.36	72	14952	82529	46588509
Polyarthritis	24.92	12.36	19	15005	6523	46664515
Serum ferritin decreased	22.86	12.36	11	15013	1641	46669397
Grip strength decreased	22.32	12.36	20	15004	8586	46662452
Hydrops foetalis	21.94	12.36	7	15017	347	46670691
Adrenal suppression	21.74	12.36	9	15015	942	46670096
Premature labour	21.25	12.36	22	15002	11277	46659761
Patent ductus arteriosus	21.15	12.36	14	15010	3848	46667190
Cerebral vasoconstriction	21.02	12.36	9	15015	1024	46670014
Impaired work ability	20.93	12.36	23	15001	12613	46658425
Ankle fracture	20.28	12.36	25	14999	15486	46655552
Large intestinal ulcer haemorrhage	19.70	12.36	5	15019	107	46670931
Maternal exposure during pregnancy	19.63	12.36	75	14949	102474	46568564
Alpha tumour necrosis factor increased	19.28	12.36	4	15020	33	46671005
Fine motor skill dysfunction	19.27	12.36	13	15011	3687	46667351
Pain	19.25	12.36	236	14788	476712	46194326
Endothelin increased	19.17	12.36	4	15020	34	46671004
Chronic gastritis	18.98	12.36	11	15013	2392	46668646
Treatment failure	18.58	12.36	69	14955	93018	46578020
Hirsutism	18.08	12.36	8	15016	986	46670052
Foetal exposure during pregnancy	17.88	12.36	34	14990	30713	46640325
Apgar score low	17.80	12.36	7	15017	642	46670396
Blood pressure fluctuation	16.89	12.36	33	14991	30415	46640623
Neuralgia	16.81	12.36	27	14997	21356	46649682
Dyspraxia	16.71	12.36	5	15019	200	46670838
Visceral leishmaniasis	16.41	12.36	6	15018	450	46670588
Nerve degeneration	16.26	12.36	4	15020	75	46670963
Migraine	15.76	12.36	54	14970	69972	46601066
Decreased vibratory sense	15.23	12.36	5	15019	272	46670766
Corneal neovascularisation	14.70	12.36	4	15020	113	46670925
Oliguria	14.61	12.36	16	15008	8743	46662295
Catheter site bruise	14.59	12.36	5	15019	310	46670728
Alkalosis	14.53	12.36	5	15019	314	46670724
White blood cell analysis abnormal	14.23	12.36	3	15021	27	46671011
Right ventricular hypertrophy	14.13	12.36	6	15018	669	46670369
Mydriasis	13.78	12.36	17	15007	10536	46660502
Bradycardia foetal	13.73	12.36	5	15019	371	46670667
Lymphoedema	13.11	12.36	15	15009	8597	46662441
Fibromatosis	13.02	12.36	3	15021	42	46670996
Rheumatoid arthritis	12.94	12.36	126	14898	240089	46430949
Premature rupture of membranes	12.92	12.36	11	15013	4412	46666626
Bursitis	12.87	12.36	23	15001	19819	46651219
Pulmonary valve incompetence	12.85	12.36	7	15017	1351	46669687
Metabolic acidosis	12.57	12.36	34	14990	38746	46632292
Atrial fibrillation	12.57	12.36	9	15015	103581	46567457
Ocular toxicity	12.53	12.36	5	15019	476	46670562
Gingival hypertrophy	12.52	12.36	7	15017	1422	46669616
Myoglobin blood increased	12.49	12.36	7	15017	1429	46669609

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gout	125.85	13.08	81	11820	17234	29923343
Ankylosing spondylitis	98.48	13.08	44	11857	4490	29936087
Ductus arteriosus premature closure	84.13	13.08	17	11884	95	29940482
Sacroiliitis	49.77	13.08	17	11884	843	29939734
Juvenile idiopathic arthritis	46.57	13.08	17	11884	1026	29939551
Drug hypersensitivity	43.81	13.08	89	11812	68430	29872147
Hepatitis B virus test positive	41.84	13.08	11	11890	218	29940359
Mast cell activation syndrome	39.33	13.08	9	11892	97	29940480
Hypoaldosteronism	39.21	13.08	10	11891	175	29940402
Drug ineffective	35.73	13.08	244	11657	340143	29600434
Arthralgia	34.19	13.08	125	11776	135666	29804911
Duodenal perforation	33.76	13.08	14	11887	1190	29939387
Neonatal disorder	33.72	13.08	13	11888	913	29939664
Exostosis	32.31	13.08	19	11882	3436	29937141
Death	31.45	13.08	59	11842	357224	29583353
Chest expansion decreased	31.42	13.08	8	11893	139	29940438
Axial spondyloarthritis	30.36	13.08	8	11893	160	29940417
Benign abdominal neoplasm	29.53	13.08	7	11894	89	29940488
Gouty arthritis	28.68	13.08	12	11889	1043	29939534
Premature baby	25.02	13.08	32	11869	16659	29923918
Placental transfusion syndrome	24.55	13.08	4	11897	4	29940573
Xanthelasma	24.09	13.08	6	11895	95	29940482
Gastric haemorrhage	22.42	13.08	23	11878	9444	29931133
Hydrops foetalis	22.36	13.08	7	11894	263	29940314
Coarctation of the aorta	22.13	13.08	8	11893	469	29940108
Gastrointestinal haemorrhage	21.97	13.08	78	11823	83368	29857209
Caesarean section	20.64	13.08	12	11889	2125	29938452
Tendon disorder	19.84	13.08	12	11889	2284	29938293
Enthesopathy	19.64	13.08	13	11888	2893	29937684
Ankle fracture	19.20	13.08	14	11887	3637	29936940
Thoracic vertebral fracture	19.19	13.08	10	11891	1430	29939147
Tricuspid valve incompetence	18.72	13.08	20	11881	8603	29931974
Osteopenia	18.27	13.08	15	11886	4633	29935944
Gastric ulcer	18.12	13.08	26	11875	15095	29925482
Water intoxication	18.11	13.08	7	11894	495	29940082
Gastric bypass	18.04	13.08	6	11895	274	29940303
Joint swelling	18.00	13.08	50	11851	46896	29893681
Drug tolerance	17.91	13.08	11	11890	2151	29938426
Procedural vomiting	17.69	13.08	5	11896	131	29940446
Joint range of motion decreased	17.21	13.08	16	11885	5829	29934748
Arthritis	17.14	13.08	33	11868	24368	29916209
Therapeutic product effect incomplete	17.09	13.08	40	11861	33794	29906783
Pulmonary sarcoidosis	17.06	13.08	7	11894	579	29939998
Synovitis	16.66	13.08	20	11881	9763	29930814
Iridocyclitis	16.56	13.08	9	11892	1400	29939177
Joint space narrowing	16.52	13.08	4	11897	56	29940521
Duodenal ulcer	16.47	13.08	20	11881	9881	29930696
Myofascial pain syndrome	16.47	13.08	6	11895	360	29940217
Burns second degree	16.42	13.08	6	11895	363	29940214
Patent ductus arteriosus	16.32	13.08	12	11889	3157	29937420
Sensitivity to weather change	16.29	13.08	9	11892	1445	29939132
Stillbirth	16.04	13.08	5	11896	185	29940392
Tobacco abuse	15.92	13.08	6	11895	396	29940181
Osteoarthritis	15.66	13.08	27	11874	18322	29922255
Sinusitis aspergillus	15.63	13.08	4	11897	71	29940506
Intraventricular haemorrhage neonatal	15.55	13.08	5	11896	205	29940372
Foot fracture	15.44	13.08	13	11888	4159	29936418
Intracranial pressure increased	15.29	13.08	12	11889	3478	29937099
Oromandibular dystonia	15.07	13.08	6	11895	459	29940118
Melaena	14.93	13.08	37	11864	32400	29908177
Adulterated product	14.26	13.08	3	11898	21	29940556
Psoriasis	14.10	13.08	43	11858	42463	29898114
Foetal distress syndrome	13.54	13.08	7	11894	984	29939593
Physical deconditioning	13.26	13.08	6	11895	630	29939947
Cardiomegaly	13.24	13.08	22	11879	14487	29926090

Pharmacologic Action:

Source	Code	Description
ATC	C01EB03	CARDIOVASCULAR SYSTEM CARDIAC THERAPY OTHER CARDIAC PREPARATIONS Other cardiac preparations
ATC	M01AB01	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Acetic acid derivatives and related substances
ATC	M02AA23	MUSCULO-SKELETAL SYSTEM TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN Antiinflammatory preparations, non-steroids for topical use
ATC	S01BC01	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Antiinflammatory agents, non-steroids
ATC	M01AB51	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Acetic acid derivatives and related substances
ATC	S01CC02	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION Antiinflammatory agents, non-steroids and antiinfectives in combination
FDA CS	M0001335	Anti-Inflammatory Agents, Non-Steroidal
FDA MoA	N0000000160	Cyclooxygenase Inhibitors
FDA EPC	N0000175722	Nonsteroidal Anti-inflammatory Drug
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D016861	Cyclooxygenase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006074	Gout Suppressants
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D012102	Reproductive Control Agents
MeSH PA	D018689	Sensory System Agents
MeSH PA	D015149	Tocolytic Agents
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory drugs
CHEBI has role	CHEBI:35544	cyclooxygenase inhibitors
CHEBI has role	CHEBI:35703	xenobiotic
CHEBI has role	CHEBI:35845	gout suppressants
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:76206	xenobiotic metabolites
CHEBI has role	CHEBI:78298	environmental contaminants

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Ankylosing spondylitis	indication	9631008	DOID:7147
Tendinitis	indication	34840004	DOID:971
Tenosynovitis	indication	67801009	DOID:970
Rheumatoid arthritis	indication	69896004	DOID:7148
Patent ductus arteriosus	indication	83330001	DOID:13832
Bursitis	indication	84017003	DOID:2965
Gout	indication	90560007	DOID:13189
Bursitis of shoulder	indication	239961006
Osteoarthritis	indication	396275006
Synovitis	indication	416209007	DOID:2703
Shoulder Tendonitis	indication
Pericarditis	off-label use	3238004	DOID:1787
Premature labor	off-label use	6383007
Renal colic	off-label use	7093002
Pseudoprimary hyperaldosteronism	off-label use	71275003
Nephrogenic diabetes insipidus	off-label use	111395007	DOID:12387
Dysmenorrhea	off-label use	266599000
Fever	off-label use	386661006
Twin reversal arterial perfusion syndrome	off-label use	417006004
Necrotizing enterocolitis in fetus OR newborn	contraindication	2707005
Proctitis	contraindication	3951002	DOID:3127
Acute hemorrhage	contraindication	8573003
Rectal hemorrhage	contraindication	12063002
Hyperkalemia	contraindication	14140009
Myocardial infarction	contraindication	22298006	DOID:5844
Parkinsonism	contraindication	32798002
Dehydration	contraindication	34095006
Depressive disorder	contraindication	35489007
Hypertensive disorder	contraindication	38341003	DOID:10763
Gastrointestinal ulcer	contraindication	40845000
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Duodenal ulcer disease	contraindication	51868009	DOID:1724
Gastrointestinal perforation	contraindication	51875005
Stomatitis	contraindication	61170000	DOID:9637
Ulcerative colitis	contraindication	64766004	DOID:8577
Blood coagulation disorder	contraindication	64779008	DOID:1247
Hemorrhoids	contraindication	70153002	DOID:9746
Corneal deposit	contraindication	74460005	DOID:11547
Gastrointestinal hemorrhage	contraindication	74474003
Heart failure	contraindication	84114007	DOID:6000
Epilepsy	contraindication	84757009	DOID:1826
Bacterial infectious disease	contraindication	87628006
Hyponatremia	contraindication	89627008
Kidney disease	contraindication	90708001	DOID:557
Blurring of visual image	contraindication	111516008
Seizure disorder	contraindication	128613002
Liver function tests abnormal	contraindication	166603001
Asthma	contraindication	195967001	DOID:2841
Sepsis of the newborn	contraindication	206376005
Coronary artery bypass graft	contraindication	232717009
Disease of liver	contraindication	235856003	DOID:409
Esophageal dysmotility	contraindication	266434009	DOID:9192
Cerebral hemorrhage	contraindication	274100004
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Malignant tumor of colon	contraindication	363406005	DOID:219
Cardiovascular event risk	contraindication	395112001
Gastric ulcer	contraindication	397825006	DOID:10808
Diverticular disease	contraindication	397881000
Smokes tobacco daily	contraindication	449868002
Psychiatric Disturbance	contraindication
Intraventricular Hemorrhage In Newborn	contraindication
Congenital Heart Defect Requiring Open Patent Ductus Arteriosus	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.45	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN	INHIBITOR	IC50	6.33	WOMBAT-PK	CHEMBL
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN	INHIBITOR	IC50	7.21	WOMBAT-PK	CHEMBL
Prostaglandin D2 receptor 2	GPCR	Q9Y5Y4	PD2R2_HUMAN		Ki	6.53	WOMBAT-PK
Aldo-keto reductase family 1 member C3	Enzyme	P42330	AK1C3_HUMAN		IC50	7	CHEMBL
Interleukin-8	Cytokine	P10145	IL8_HUMAN		IC50	7.30	CHEMBL
Prostaglandin E synthase	Enzyme	O14684	PTGES_HUMAN		IC50	4.39	CHEMBL
Aldo-keto reductase family 1 member C4	Enzyme	P17516	AK1C4_HUMAN		IC50	4.27	CHEMBL
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN		EC50	9.85	CHEMBL
Multidrug resistance-associated protein 1	Transporter	P33527	MRP1_HUMAN		IC50	4.92	CHEMBL
Aldo-keto reductase family 1 member C2	Enzyme	P52895	AK1C2_HUMAN		IC50	4.44	CHEMBL
Dehydrogenase/reductase SDR family member 9	Enzyme	Q9BPW9	DHRS9_HUMAN		IC50	4.85	CHEMBL
Lactoylglutathione lyase	Enzyme	Q04760	LGUL_HUMAN		Ki	4.74	CHEMBL
Aldose reductase	Enzyme	P15121	ALDR_HUMAN		IC50	5.22	CHEMBL
Potassium voltage-gated channel subfamily A member 7	Ion channel	Q96RP8	KCNA7_HUMAN		Ki	7.50	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.49	CHEMBL
Prostaglandin E2 receptor EP2 subtype	GPCR	P43116	PE2R2_HUMAN		Ki	7.69	PDSP
Peroxisome proliferator-activated receptor gamma	Nuclear hormone receptor	P37231	PPARG_HUMAN	AGONIST	Kd	7.38	IUPHAR
Aldose reductase	Enzyme		ALDR_RAT		IC50	5.44	DRUG MATRIX
Aldose reductase	Enzyme		ALDR_BOVIN		IC50	5.30	CHEMBL
Prostaglandin G/H synthase (cyclooxygenase)	Enzyme		PGH1_SHEEP PGH2_SHEEP		IC50	6.82	CHEMBL
Prostaglandin G/H synthase 1	Enzyme		PGH1_SHEEP		Ki	5.10	CHEMBL
Prostaglandin-H2 D-isomerase	Enzyme		PTGDS_MOUSE		IC50	6.30	CHEMBL
Prostaglandin G/H synthase 2	Enzyme		PGH2_SHEEP		IC50	6.47	CHEMBL
Prostaglandin G/H synthase 2	Enzyme		PGH2_MOUSE		IC50	8.19	CHEMBL
Prostaglandin G/H synthase 1	Enzyme		PGH1_MOUSE		IC50	8.70	CHEMBL
Cyclooxygenase	Enzyme		PGH1_RAT PGH2_RAT		IC50	7	CHEMBL
Prostaglandin G/H synthase 2	Enzyme		PGH2_RAT		IC50	8	CHEMBL
Cyclooxygenase	Enzyme		PGH1_BOVIN PGH2_BOVIN		IC50	6.37	CHEMBL
Prostaglandin G/H synthase 1	Enzyme		PGH1_RAT		IC50	8.22	CHEMBL
Prostaglandin G/H synthase 1	Enzyme		PGH1_BOVIN		IC50	8.39	CHEMBL
Nitric oxide synthase, inducible	Enzyme		NOS2_MOUSE		IC50	4.70	CHEMBL
Prostaglandin D2 receptor 2	Unclassified		PD2R2_MOUSE	AGONIST	Ki	6	IUPHAR

External reference:

ID	Source
D00141	KEGG_DRUG
74252-25-8	SECONDARY_CAS_RN
4017890	VANDF
4017891	VANDF
C0700798	UMLSCUI
CHEBI:49662	CHEBI
IMN	PDB_CHEM_ID
CHEMBL6	ChEMBL_ID
CHEMBL3989410	ChEMBL_ID
DB00328	DRUGBANK_ID
D007213	MESH_DESCRIPTOR_UI
1909	IUPHAR_LIGAND_ID
1524	INN_ID
XXE1CET956	UNII
3715	PUBCHEM_CID
1294612	RXNORM
2387	MMSL
2393	MMSL
4877	MMSL
d00039	MMSL
002373	NDDF
002374	NDDF
373513008	SNOMEDCT_US
60149003	SNOMEDCT_US
783274005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1113	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 mg	INTRAVENOUS	ANDA	13 sections
INDOMETHACIN	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0176	SUPPOSITORY	50 mg	RECTAL	ANDA	14 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-083	CAPSULE	50 mg	ORAL	ANDA	27 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-919	CAPSULE, EXTENDED RELEASE	75 mg	ORAL	ANDA	12 sections
Indomethacin	Human Prescription Drug Label	1	10544-935	CAPSULE, EXTENDED RELEASE	75 mg	ORAL	ANDA	24 sections
INDOMETHACIN	HUMAN PRESCRIPTION DRUG LABEL	1	10702-016	CAPSULE, EXTENDED RELEASE	75 mg	ORAL	ANDA	28 sections
INDOMETHACIN ER	HUMAN PRESCRIPTION DRUG LABEL	1	12634-160	CAPSULE	75 mg	ORAL	ANDA	14 sections
INDOMETHACIN ER	HUMAN PRESCRIPTION DRUG LABEL	1	12634-838	CAPSULE	75 mg	ORAL	ANDA	14 sections
INDOMETHACIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-130	CAPSULE	50 mg	ORAL	ANDA	24 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-522	CAPSULE	25 mg	ORAL	ANDA	27 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-523	CAPSULE	50 mg	ORAL	ANDA	23 sections
Indomethacin	Human Prescription Drug Label	1	31722-542	CAPSULE	25 mg	ORAL	ANDA	27 sections
Indomethacin	Human Prescription Drug Label	1	31722-543	CAPSULE	50 mg	ORAL	ANDA	27 sections
Indomethacin	Human Prescription Drug Label	1	31722-565	CAPSULE, EXTENDED RELEASE	75 mg	ORAL	ANDA	24 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	35356-697	CAPSULE	50 mg	ORAL	ANDA	27 sections
INDOCIN	HUMAN PRESCRIPTION DRUG LABEL	1	42211-101	SUSPENSION	25 mg	ORAL	NDA	28 sections
INDOCIN	HUMAN PRESCRIPTION DRUG LABEL	1	42211-102	SUPPOSITORY	50 mg	RECTAL	ANDA	29 sections
Tivorbex	HUMAN PRESCRIPTION DRUG LABEL	1	42211-201	CAPSULE	20 mg	ORAL	NDA	28 sections
Tivorbex	HUMAN PRESCRIPTION DRUG LABEL	1	42211-202	CAPSULE	40 mg	ORAL	NDA	28 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	42254-081	CAPSULE	50 mg	ORAL	ANDA	27 sections
INDOMETHACIN	HUMAN PRESCRIPTION DRUG LABEL	1	42254-237	CAPSULE	25 mg	ORAL	ANDA	25 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	43063-368	CAPSULE	25 mg	ORAL	ANDA	29 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	43063-773	CAPSULE	25 mg	ORAL	ANDA	27 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	43063-777	CAPSULE	50 mg	ORAL	ANDA	27 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	43063-929	CAPSULE	50 mg	ORAL	ANDA	29 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	43063-930	CAPSULE	50 mg	ORAL	ANDA	29 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	49349-776	CAPSULE	50 mg	ORAL	ANDA	24 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	49999-371	CAPSULE, EXTENDED RELEASE	75 mg	ORAL	ANDA	12 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0051	CAPSULE	50 mg	ORAL	ANDA	32 sections
Indomethacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0053	CAPSULE	25 mg	ORAL	ANDA	32 sections